Immuneering Corporation announced on September 16, 2025, the appointment of Thomas J. Schall, Ph.D., as Chairman of its Board of Directors. Dr. Schall is a renowned biotech executive and scientist with over 30 years of leadership experience in drug discovery and development.
Dr. Schall is recognized as the founder and former CEO and Chairman of ChemoCentryx, where he led the development and FDA approval of Tavneos, a first-in-class oral therapy. ChemoCentryx was subsequently acquired by Amgen in 2022 for nearly $4 billion, demonstrating Dr. Schall's track record in bringing therapies to market and creating significant value.
Having served on Immuneering’s Board of Directors since March 2024, Dr. Schall's appointment to Chairman comes at a pivotal time as Immuneering advances its lead program, atebimetinib, through late-stage development. His expertise in navigating regulatory pathways and commercialization will be critical as the company prepares for pivotal studies and potential registration filings.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.